Key result
Intravenous oxycodone successfully alleviated medically refractory dyspnea in a patient with end-stage heart failure and renal insufficiency, reducing the Modified Borg Scale score from 10 to 2.
Why the study?
Does intravenous oxycodone improve dyspnea in a patient with end-stage heart failure and renal insufficiency?
Case Report (n=1)
No
Does intravenous oxycodone improve dyspnea in a patient with end-stage heart failure and renal insufficiency?
Oxycodone may be a safe and effective palliative option for managing dyspnea in patients with end-stage heart failure and renal insufficiency who are at high risk for morphine-induced respiratory depression.
Hypothesis-generating for IV oxycodone in refractory dyspnea with end-stage HF and renal failure; should not change practice without controlled trials.
A 67-year-old man with dilated cardiomyopathy and renal insufficiency was admitted to our hospital with dyspnea secondary to end-stage heart failure. We introduced oxycodone for medically refractory dyspnea instead of morphine because of the patient's renal insufficiency. After the administration of oxycodone, his dyspnea was alleviated without any adverse opioid effects, such as respiratory depression. After treating his heart failure, he was able to leave the intensive care unit. Oxycodone may therefore be a reliable agent for the treatment of dyspnea in patients with end-stage heart failure and renal insufficiency.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2017) conducted a case report in End-stage heart failure with renal insufficiency and dyspnea (n=1). Oxycodone was evaluated on Dyspnea relief measured by Modified Borg Scale. Intravenous oxycodone successfully alleviated medically refractory dyspnea in a patient with end-stage heart failure and renal insufficiency, reducing the Modified Borg Scale score from 10 to 2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: